Fig.Ā 4From: A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosisFrequency of CDKN2A mutations per histologic sarcoma type in Foundation Medicine dataset (nā=ā7733). Copy number changes (orange) dominate the mutational landscape with infrequent occurrences of SNVs (green) and rearrangements (purple). The overall prevalence of CDKN2A mutations in sarcoma (left most bar) is 16.7% (nā=ā7733), with the highest mutated tumor being MPNST (60.7%, nā=ā262) followed by myxofibrosarcoma (29.3%, nā=ā140), and undifferentiated pleomorphic sarcoma (26.8%, nā=ā372)Back to article page